dailyai.report

Engineered proteins for biologic medicines often fail during lengthy, expensive development cycles. New AI tools now predict protein structures and interactions to identify viable candidates faster. This shift reduces early-stage trial failures. Researchers at MIT and other labs are using these models to shorten the path from discovery to patient.